JNJ

Johnson & Johnson

• Simply Wall St·10h ago

  Has Johnson & Johnson (JNJ) Run Too Far After A 54% One-Year Surge?

• Seeking Alpha·1d ago

  Notable analyst calls this week: Dell, J&J and AMD stocks among top picks

• Simply Wall St·1d ago

  Assessing Johnson & Johnson (JNJ) Valuation After Earnings Beat Guidance Hike And Ongoing Dividend Growth

• Seeking Alpha·1d ago

  Dividend Champion, Contender, And Challenger Highlights: Week Of May 17

• TipRanks·1d ago

  Davis to become acting director of CDER after Hoeg exit, Bloomberg says

• Benzinga·1d ago

  Congressman A Big Fan Of Dividend Reinvestments: Here's His Core Blue Chip Stocks

• Seeking Alpha·1d ago

  FDA leadership fallout continues as acting CDER Director Hoeg expected to depart

• Simply Wall St·2d ago

  How Investors Are Reacting To Johnson & Johnson (JNJ) Expanding Its Coronary Lithotripsy Device Portfolio

• PR Newswire·2d ago

  Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

• Seeking Alpha·2d ago

  Biopharmas look to China, elsewhere for partnerships, R&D

• Seeking Alpha·2d ago

  Strong biopharma dealmaking market set to continue

• NASDAQ·2d ago

  Why Is Johnson & Johnson (JNJ) Down 3.5% Since Last Earnings Report?

• Seeking Alpha·2d ago

  Trump 'Most Favored Nation' drug policy risks China R&D takeover

• Benzinga·3d ago

  Trump's Drug Pricing Plan Gains Surprise Democratic Ally— Peter Welch Vows To 'Make It Happen'

• TipRanks·3d ago

  Analysts Conflicted on These Healthcare Names: Altimmune (ALT), Brookdale Senior Living (BKD) and Johnson & Johnson (JNJ)